{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:58:01Z","timestamp":1790585881676,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.rpth.2026.106927","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:53:29Z","timestamp":1787925209000},"page":"106927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Isolated A1-domain F8 large deletions are associated with favorable immune tolerance induction outcomes in children with severe hemophilia A"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-9074","authenticated-orcid":false,"given":"Zhengping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5273-145X","authenticated-orcid":false,"given":"Zhenping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-9430","authenticated-orcid":false,"given":"Jialu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinqi","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanru","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenman","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-209X","authenticated-orcid":false,"given":"Runhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106927_bib1","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1053\/j.seminhematol.2008.03.004","article-title":"Arthropathy in inhibitor patients: differences in the joint status","volume":"45","author":"Hoots","year":"2008","journal-title":"Semin Hematol"},{"key":"10.1016\/j.rpth.2026.106927_bib2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.23957","article-title":"Impact of inhibitors on hemophilia A mortality in the United States","volume":"90","author":"Walsh","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2026.106927_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/hae.14431","article-title":"Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors","volume":"28","author":"Di Minno","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106927_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12723","article-title":"F8 gene mutation spectrum in severe hemophilia A with inhibitors: a large cohort data analysis from a single center in China","volume":"6","author":"Sun","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106927_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109115","article-title":"Large deletions and small insertions and deletions in the factor VIII gene predict unfavorable immune tolerance induction outcome in people with severe hemophilia A and high-responding inhibitors","volume":"242","author":"Zuccherato","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106927_bib6","article-title":"Disease-causing 7.4 kb cis-regulatory deletion disrupting conserved non-coding sequences and their interaction with the FOXL2 promotor: implications for mutation screening","volume":"5","author":"D\u2019haene","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1016\/j.rpth.2026.106927_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1086\/426833","article-title":"Long-range control of gene expression: emerging mechanisms and disruption in disease","volume":"76","author":"Kleinjan","year":"2005","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.rpth.2026.106927_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.672564","article-title":"CRISPR\/Cas9-mediated in vivo genetic correction in a mouse model of hemophilia A","volume":"9","author":"Luo","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.rpth.2026.106927_bib9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0888-7543(05)80155-7","article-title":"Evidence for a third transcript from the human factor VIII gene","volume":"14","author":"Levinson","year":"1992","journal-title":"Genomics"},{"key":"10.1016\/j.rpth.2026.106927_bib10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3270","article-title":"Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A","volume":"19","author":"Pandey","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2026.106927_bib11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41525-025-00513-4","article-title":"Disruption of SPECC1L translation initiation by intragenic deletion: novel pathogenic mechanism in Teebi-hypertelorism syndrome","volume":"10","author":"Babai","year":"2025","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.rpth.2026.106927_bib12","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3324\/haematol.2019.239202","article-title":"Deciphering the Ets-1\/2-mediated transcriptional regulation of F8 gene identifies a minimal F8 promoter for hemophilia A gene therapy","volume":"106","author":"Fam\u00e0","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106927_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2013-12-530113","article-title":"The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics","volume":"125","author":"Sauna","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106927_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12824","article-title":"Low-dose immune tolerance induction in children with severe hemophilia A with high-titer inhibitors: type of factor 8 mutation and outcomes","volume":"6","author":"Sun","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106927_bib15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106927_bib16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2516.2009.02191.x","article-title":"Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A","volume":"16","author":"Bj\u00f6rkman","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106927_bib17","series-title":"GeneReviews\u00ae","article-title":"Hemophilia A","author":"Konkle","year":"1993"},{"key":"10.1016\/j.rpth.2026.106927_bib18","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1182\/blood-2007-08-109918","article-title":"The tertiary structure and domain organization of coagulation factor VIII","volume":"111","author":"Shen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106927_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102639","article-title":"Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial","volume":"9","author":"Li","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2026.106927_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/hae.12051","article-title":"The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?","volume":"19","author":"Ettingshausen","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106927_bib21","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1365-2516.2010.02250.x","article-title":"F8 mRNA studies in haemophilia A patients with different splice site mutations","volume":"16","author":"Castaman","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106927_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3324\/haematol.2017.178327","article-title":"Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity","volume":"103","author":"Donadon","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106927_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/bloodadvances.2016001651","article-title":"Accurate, simple, and inexpensive assays to diagnose F8 gene inversion mutations in hemophilia A patients and carriers","volume":"1","author":"Dutta","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106927_bib24","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat Protoc"},{"key":"10.1016\/j.rpth.2026.106927_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.thromres.2018.05.027","article-title":"Risk factors for inhibitor development in severe hemophilia A","volume":"168","author":"Garagiola","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106927_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103212","article-title":"Large deletions in the F8 gene predict immune tolerance induction failure in people with severe hemophilia A","volume":"9","author":"Oomen","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106927_bib27","first-page":"145","article-title":"Factor 8 gene mutation spectrum of 270 patients with hemophilia A: identification of 36 novel mutations","volume":"37","author":"Atik","year":"2020","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.rpth.2026.106927_bib28","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106927_bib29","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/bloodadvances.2020001832","article-title":"Maternal microchimerism protects hemophilia A patients from inhibitor development","volume":"4","author":"Lu","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106927_bib30","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/j.1538-7836.2009.03615.x","article-title":"Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors","volume":"7","author":"Coppola","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106927_bib31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev.immunol.21.120601.141107","article-title":"Positive and negative selection of T cells","volume":"21","author":"Starr","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.rpth.2026.106927_bib32","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/jth.13961","article-title":"Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement","volume":"16","author":"Spena","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106927_bib33","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/hmg\/2.11.1773","article-title":"Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions","volume":"2","author":"Naylor","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.rpth.2026.106927_bib34","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1016\/j.jtha.2024.08.007","article-title":"Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk","volume":"22","author":"Vir","year":"2024","journal-title":"J Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:26:33Z","timestamp":1790583993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2475037926035855"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106927","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolated A1-domain F8 large deletions are associated with favorable immune tolerance induction outcomes in children with severe hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106927"}}